{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-23-000096","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.438869+00:00","generated_at":"2026-06-12T00:57:05.081526+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ClearPoint Neuro Q2 revenue record $6.0M (+14% YoY); biologics growth 40%; reaffirms FY guide $25-27M","bullets":["Record Q2 revenue $6.0M, up 14% YoY; biologics & drug delivery revenue $3.4M (+40%).","Gross margin fell to 53% from 63% due to lower-margin preclinical services and facility transition costs.","Operating expenses rose to $10.3M from $7.5M on higher headcount, stock comp, and product development.","Cash & equivalents $26.5M at June 30, down from $37.5M at Dec 2022; operating cash burn $10.8M.","Reaffirmed FY2023 revenue guidance $25-27M; CEO outlines five key milestones for H2."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-23-000096","json":"https://secwatch.observer/filing/0001285550-23-000096.json","markdown":"https://secwatch.observer/filing/0001285550-23-000096.md","text":"https://secwatch.observer/filing/0001285550-23-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/0001285550-23-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/clpt-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T00:57:05.081526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dec16a214e2b2c4f8f4c8aa1922f873e6750509b","claim":"ClearPoint Neuro, Inc. reported second quarter ended June 30, 2023 results: revenue record quarterly revenue of $6.0 million. Guidance reaffirmed.","evidence_excerpt":"and delivery to the brain, today announced financial results for its second quarter ended June 30, 2023. Second Quarter Highlights • Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase; • Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase; • Announced an example of a milestone-based","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000096/0001285550-23-000096-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"record quarterly revenue of $6.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}